Signature of the Risk Profile of Mortality in a Hospital Cohort of Patients With Metabolic Diseases

Study Overview
=================
Brief Summary
-----------------
Epidemiological studies are usually conducted in the general population in adults without complications or pathology at baseline. The results obtained are therefore often better designed for primary prevention use. The prediction of mortality risk in patients with complications and requiring hospital follow-up is less well known. The study purpose is to determine a mortality risk profile in a hospital cohort of patients with pathologies associated with metabolic diseases. Today the multimaker scores based on a panel of biomarkers - have significantly improved the discriminating power of prediction models existing in many pathologies. It is no longer a single biomarker that can improve risk prediction but a complete and cross-sectional profile that is sought after. We aim to establish a personalised mortality risk profile by combining clinical and biological parameters including metabolomics, genetics, transcriptomics and epigenomics by high throughput screening of biological samples.

Detailed Description
-----------------
The prediction of the onset of diabetes and metabolic complications, especially cardiovascular, renal, or hepatic, is a major challenge to optimize the management of this disease. Teams from the University Hospital of Lille have developed the Integra cohort study to identify the clinical and biological determinants of the occurrence of these complications and the mortality of patients with metabolic disorders. The aim of the study is to identify clinico-biological determinants that are able to predict the occurence of death, cardiovascular events as well as hepatic or nephrotic one. Follow-up data will be collected from National System of Health Data (SNDS) where data concerning hospitalisations, medical consultations and treatments are registered. Biological samples are collected at baseline for a large OMICs analysis (metabolomics, genetics, transcriptomics and epigenomics) that would feed our predictive scoring system. This project will allow us to describe new models of prediction of metabolic diseases and its complications, and to offer adapted and personalised methods of management, which can slow the progression of the disease and improve its prognosis.

Official Title
-----------------
Signature of the Risk Profile of Mortality in a Hospital Cohort of Patients With Metabolic Diseases

Conditions
-----------------
Metabolic Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diabetic: antecedent - treatment - or glycemia> = 1.26 g / dl - or HbA1C> = 6.5% and or Obese: BMI> = 30 and or Metabolic syndrome defined AND Patient having given written consent to participate in the study or collection of the consent of the witness Social insured patient (excluding AME) Patient willing to comply with all procedures of the study and its duration AND Patient also presenting a pathology among: Cardiology: Coronary patient(history of myocardial infarction, coronary bypass, or coronary angioplasty or stenosis greater than 50% on an epicardial vessel documented on coronary angiography) Patient with systolic or diastolic heart failure Patient with atrial fibrillation Patient with aortic stenosis (Vmax> 2.5 m / s) Patient with high blood pressure neurology: ischemic stroke intracerebral hemorrhage transient ischemic attack diabetology: Obesity without diabetes Diabetes T2 T1 diabetes Monogenic Diabetes / MODY African Diabetes Diabetes secondary to pancreatopathy / liver cirrhosis Diabetes post transplantation / post immunotherapy Diabetes associated with Steinert's disease hepatology: hepatological pathology nephrology: nephrology Exclusion Criteria: Unscheduled hospitalization less than 3 months old Ongoing treatment : Cytotoxic chemotherapy Radiotherapy HIV and / or HCV and / or active HBV infection OMS score> = 2 Pregnant woman

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Metabolic Patient<br>Patients with a metabolic desease, defined as Metabolic Syndrom Diabetic Obese | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of death | The number of patients dead according to national database | at 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurrence of macrovascular complications (composite criteria) | composite criteria: cardiovascular death, myocardial infarction, stroke, coronary revascularization, peripheral revascularization, amputation) | at 10 years | 
| hospitalization for heart failure | The number of patients that has been hospitalized for heart failure since the end of the study according to national database | at 10 years | 
| Occurence of renal microvasculare complications (composite criteria) | composite criteria: renal transplantation, dialysis, GFR >60, Albuminuria | at 10 years | 
| Occurrence of liver complications(composite endpoint) | composite endpoint: hepatic fibrosis, cirrhosis, HCC, death from liver | at 10 years | 
| Occurrence of hemorrhages measured by BARC >3 bleeding | composite endpoint : CABG-related bleeding (Perioperative intracranial bleeding within 48 h / Reoperation after closure of sternotomy for the purpose of controlling bleeding / Transfusion of<5 U whole blood or packed red blood cells within a 48-hperiod / Chest tube output>=2L within a 24-h period) or Fatal Bleeding (Probable fatal bleeding; no autopsy or imaging confirmation butclinically suspicious / Definite fatal bleeding; overt bleeding or autopsy or imagingconfirmation) | at 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diabetic, CardioVascular Disease, morbi-mortality, Hospital Cohort